RAS inhibitor adherence is a quality and performance metric within the STAR rating system that evaluates the percentage of Medicare Part D plan and Medicare Advantage plan members over the age of 18 who filled prescriptions for a renin – angiotensin system (RAS) antagonist (ACE inhibitors, ARBs, or direct renin inhibitors) to cover ≥80% of days in the measurement period. Adherence to RAS inhibitors is a cornerstone of clinical quality and one of the most heavily weighted measures in the STAR Rating system – triple weighted and representing nearly 30 percent of the total Part D score – so it is essential that organizations understand how to systematically improve performance in this metric.
AAVBC’s Quick Reference Guide distills regulatory expectations, scoring methodology, measure weighting, best practices and performance benchmarks for RAS inhibitor adherence. These guides provide organizations with a clear understanding of RAS inhibitor adherence so that they can effectively implement it into their clinical practice; in doing so, they can maximize their financial incentives, market competitiveness, and regulatory compliance in the ever-evolving Medicare Advantage landscape.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of RAS inhibitor adherence — moving far beyond quick-reference essentials. These guides provide an integrated review of measurement importance and impact, clinical integrations, technical details, challenges and barriers, strategies for team coordination and quality improvement as well as regulatory and financial considerations. The Deep-Dives combine evidence-informed clinical guidance with practical operational tools to support a deeper understanding of RAS inhibitor adherence and provide care teams with strategies to thrive within a value-based model.
RAS inhibitor adherence is a quality and performance metric within the STAR rating system that evaluates the percentage of Medicare Part D plan and Medicare Advantage plan members over the age of 18 who filled prescriptions for a renin – angiotensin system (RAS) antagonist (ACE inhibitors, ARBs, or direct renin inhibitors) to cover ≥80% of days in the measurement period. Adherence to RAS inhibitors is a cornerstone of clinical quality and one of the most heavily weighted measures in the STAR Rating system – triple weighted and representing nearly 30 percent of the total Part D score – so it is essential that organizations understand how to systematically improve performance in this metric.
AAVBC’s Quick Reference Guide distills regulatory expectations, scoring methodology, measure weighting, best practices and performance benchmarks for RAS inhibitor adherence. These guides provide organizations with a clear understanding of RAS inhibitor adherence so that they can effectively implement it into their clinical practice; in doing so, they can maximize their financial incentives, market competitiveness, and regulatory compliance in the ever-evolving Medicare Advantage landscape.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of RAS inhibitor adherence — moving far beyond quick-reference essentials. These guides provide an integrated review of measurement importance and impact, clinical integrations, technical details, challenges and barriers, strategies for team coordination and quality improvement as well as regulatory and financial considerations. The Deep-Dives combine evidence-informed clinical guidance with practical operational tools to support a deeper understanding of RAS inhibitor adherence and provide care teams with strategies to thrive within a value-based model.
